Showing results (1-10 of 42) with videos related to
Sort By:
Pageof 5
Neuro-Degenerative Diseases|December 14, 2007
Campath-1H treatment of multiple sclerosisJoanne L Jones, Alasdair J ColesExperimental Neurology|June 16, 2010
New treatment strategies in multiple sclerosisJoanne L Jones, Alasdair J ColesExperimental Neurology|May 6, 2014
Mode of action and clinical studies with alemtuzumabJoanne L Jones, Alasdair J ColesEnvironmental Science & Technology|June 22, 2002
Polychlorinated dibenzo-p-dioxin and furan (PCDD/F) uptake by pastureGareth O Thomas, Joanne L Jones, Kevin C JonesNeuronal Signaling|September 23, 2021
The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's diseaseShamma Qarin, Sarah K Howlett, Joanne L Jones, et al.Frontiers in Immunology|October 1, 2025
TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBDRabia S Mousa, Pietro Invernizzi, Joanne L Jones, et al.Journal of Neurology|October 19, 2015
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case seriesLaura Azzopardi, Amanda L Cox, Claire L McCarthy, et al.Environmental Science & Technology|April 12, 2005
Emission factors and importance of PCDD/Fs, PCBs, PCNs, PAHs and PM10 from the domestic burning of coal and wood in the U.KRobert G M Lee, Peter Coleman, Joanne L Jones, et al.Journal of Clinical Immunology|September 19, 2009
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosisSara A J Thompson, Joanne L Jones, Amanda L Cox, et al.Neurology|August 9, 2013
Immune competence after alemtuzumab treatment of multiple sclerosisClaire L McCarthy, Orla Tuohy, D Alastair S Compston, et al.Pageof 5